2023 World Conference on Lung Cancer (Posters)-EP06.03. Implementing Next Generation Sequencing for Lung Cancer Patients in Mexico: A Real-World Study from Puebla

EP06.03. Implementing Next Generation Sequencing for Lung Cancer Patients in Mexico: A Real-World Study from Puebla - PDF(Abstract)

Back to course

Pdf Summary

This study presents real-world data on the implementation of Next Generation Sequencing (NGS) for lung cancer patients in Mexico. The researchers collected clinical and genomic information from 35 patients with lung cancer who underwent NGS testing at an oncology center in Puebla, Mexico. The results showed that the most common histological subtype was adenocarcinoma (71.43%), followed by squamous cell carcinoma (11.43%) and neuroendocrine carcinoma (11.43%). PD-L1 expression was measured in 57.14% of cases, and the most frequent pathogenic variants identified were EML4-ALK fusion, EGFR amplification, and EGFR L858R mutation.<br /><br />The study found that NGS recommended an FDA-approved drug or clinical trial in 85.71% of cases. Patients who only had clinical trials available had the worst progression-free survival (PFS). The median PFS for the entire cohort was 8.16 months. A correlation matrix analysis revealed a positive relationship between squamous cell carcinoma and tumor mutational burden (TMB) and between neuroendocrine carcinoma and PFS.<br /><br />The researchers concluded that NGS can guide therapeutic decisions and potentially improve outcomes for lung cancer patients. They emphasized the need for further research with larger sample sizes to validate their findings and expand the understanding of the genomic landscape of lung cancer in Mexico.<br /><br />Overall, this study provides important real-world data on the use of NGS in the Mexican population and its potential impact on therapeutic decisions and patient outcomes in lung cancer.

Asset Subtitle

Iván Romarico González-Espinoza

Meta Tag

Speaker Iván Romarico González-Espinoza

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

Next Generation Sequencing

lung cancer patients

Mexico

clinical and genomic information

histological subtype

PD-L1 expression

pathogenic variants

FDA-approved drug

progression-free survival

therapeutic decisions